YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath

Completed

Conditions: Dyspnea
Pulmonary Edema
Pneumonia

Interventions: Procedure: Lung ultrasound
Device: ultrasound

First Posted Date: 2015-12-23

Last Posted Date: 2020-03-23

Lead Sponsor: Yale University

Target Recruit Count: 69

Registration Number: NCT02638649

Locations: 🇺🇸
Yale-New Haven Hospital-Saint Raphael Campus, New Haven, Connecticut, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer

Phase 1

Withdrawn

Conditions: Colorectal Cancer

Interventions: Drug: cetuximab and savolitinib

First Posted Date: 2015-12-15

Last Posted Date: 2017-10-26

Lead Sponsor: Yale University

Registration Number: NCT02630420

Regulation of Arginine-vasopressin (AVP)

Not Applicable

Completed

Conditions: Schizophrenia
Depression

Interventions: Other: Procedural

First Posted Date: 2015-12-10

Last Posted Date: 2015-12-10

Lead Sponsor: Yale University

Target Recruit Count: 25

Registration Number: NCT02626832

Locations: 🇺🇸
The John Pierce Laboratory, New Haven, Connecticut, United States
🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Improving Cancer Family Caregivers' Knowledge and Communication About Care Options

Not Applicable

Completed

Conditions: Family Caregivers

Interventions: Other: Symptom Management Toolkit

First Posted Date: 2015-11-26

Last Posted Date: 2017-03-07

Lead Sponsor: Yale University

Target Recruit Count: 35

Registration Number: NCT02616107

Locations: 🇺🇸
Smilow Cancer Hospital, New Haven, Connecticut, United States

Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse

Not Applicable

Completed

Conditions: Alcohol Dependence

Interventions: Device: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
Device: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2

First Posted Date: 2015-11-26

Last Posted Date: 2023-04-18

Lead Sponsor: Yale University

Target Recruit Count: 224

Registration Number: NCT02616094

Locations: 🇺🇸
Yale Stress Center, New Haven, Connecticut, United States

Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-small Cell Lung

Interventions: Drug: Carboplatin
Drug: Nab-paclitaxel

First Posted Date: 2015-10-28

Last Posted Date: 2018-02-28

Lead Sponsor: Yale University

Target Recruit Count: 3

Registration Number: NCT02590003

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

Completed

Conditions: Opioid-related Disorders
Depression
HIV Infections
Hepatitis C, Chronic

First Posted Date: 2015-10-22

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 209

Registration Number: NCT02583243

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Ketamine Infusion for Adolescent Depression and Anxiety

Phase 4

Completed

Conditions: Major Depressive Disorder
Anxiety Disorder

Interventions: Drug: Ketamine
Drug: Midazolam

First Posted Date: 2015-10-20

Last Posted Date: 2020-07-14

Lead Sponsor: Yale University

Target Recruit Count: 17

Registration Number: NCT02579928

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States
🇺🇸
Hospital Research Unit at the Yale New Haven Hospital, New Haven, Connecticut, United States

Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care

Not Applicable

Completed

Conditions: Overweight
Obesity

Interventions: Behavioral: motivational interviewing and nutrition

First Posted Date: 2015-10-16

Last Posted Date: 2020-03-30

Lead Sponsor: Yale University

Target Recruit Count: 31

Registration Number: NCT02578199

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Active Pregnenolone
Drug: Active Delta-9-THC
Drug: Placebo

First Posted Date: 2015-10-15

Last Posted Date: 2023-08-07

Lead Sponsor: Yale University

Target Recruit Count: 38

Registration Number: NCT02576912

Locations: 🇺🇸
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy